Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : ZKAB001 (Socazolimab) (anti-PD-L1 monoclonal antibody) was discovered by Sorrento from its fully human antibody G-MABTM library and licensed by China Oncology Focus Limited (“COF”), a Lee’s Pharm subsidiary, for the Great China Territories.
Product Name : ZKAB001
Product Type : Antibody
Upfront Cash : Inapplicable
May 17, 2022
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Lee’s 1st Patient Dosed Socazolimab, Licensed From Sorrento Treatment Cancer
Details : The initiation of this Phase 3 trial is based on the very encouraging results from an earlier Phase Ib trial in which Socazolimab combined with carboplatin and etoposide showed a promising efficacy and safety profile in patients with extensive-stage smal...
Product Name : ZKAB001
Product Type : Antibody
Upfront Cash : Inapplicable
July 23, 2021
Lead Product(s) : Socazolimab,Carboplatin,Etoposide
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Sorrento Therapeutics
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
